Skip to content

Study · Randomized controlled trial · n = 98 · 1998

8 results

Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial.

Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS

Hepatology (Baltimore, Md.)1 May 1998Cited by 96 (Europe PMC)

PMID9581695 (opens in a new tab)DOI10.1002/hep.510270527 (opens in a new tab)PepBankPUB-09581695
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In chronic hepatitis B, complete response rates were similar among the three groups at the end of therapy.

    In plain wordsIn people with chronic hepatitis B, complete virus clearance rates were similar with thymosin alpha1 and with no treatment at the end of therapy.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeComplete virological response at end of therapy
    Study

    n = 98

    Comparator
    No treatment (control)
    Outcome group
    Antiviral activity · Liver
    Studied dose
    1.6 mg twice weekly · subcutaneous · 26 or 52 weeksAs given in this study (human).

    Source sentences

    Summary
    although complete response rates among these three groups were similar when first assessed at the end of therapy.
    1 context sentence
    Summary · context
    Ninety-eight patients with clinicopathologically proven chronic hepatitis B were randomly allocated to 3 groups
  2. 02HumanRandomized controlled trialEfficacy outcome

    In chronic hepatitis B, blinded histological assessment showed a significant improvement in treated patients.

    In plain wordsIn people with chronic hepatitis B, blinded review of liver tissue showed significant improvement in treated patients.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseHistological improvement
    Study

    n = 98

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    1.6 mg twice weekly · subcutaneous · 26 or 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Blinded histological assessment showed a significant improvement in treated patients, particularly in lobular necroinflammation and scores excluding fibrosis.
    1 context sentence
    Summary · context
    Ninety-eight patients with clinicopathologically proven chronic hepatitis B were randomly allocated to 3 groups
  3. 03HumanRandomized controlled trialEfficacy outcome

    In chronic hepatitis B, histological improvement in treated patients was particularly marked in lobular necroinflammation.

    In plain wordsIn people with chronic hepatitis B, liver tissue improvement in treated patients was especially clear for lobular inflammation and cell damage.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseLobular necroinflammation
    Study

    n = 98

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    1.6 mg twice weekly · subcutaneous · 26 or 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Blinded histological assessment showed a significant improvement in treated patients, particularly in lobular necroinflammation and scores excluding fibrosis.
    1 context sentence
    Summary · context
    Ninety-eight patients with clinicopathologically proven chronic hepatitis B were randomly allocated to 3 groups
  4. 04HumanRandomized controlled trialEfficacy outcome

    In chronic hepatitis B, histological improvement in treated patients was particularly marked in scores that exclude fibrosis.

    In plain wordsIn people with chronic hepatitis B, liver tissue scores that exclude scarring improved especially in treated patients.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseHistological scores excluding fibrosis
    Study

    n = 98

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    1.6 mg twice weekly · subcutaneous · 26 or 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Blinded histological assessment showed a significant improvement in treated patients, particularly in lobular necroinflammation and scores excluding fibrosis.
    1 context sentence
    Summary · context
    Ninety-eight patients with clinicopathologically proven chronic hepatitis B were randomly allocated to 3 groups
  5. 05HumanRandomized controlled trialSafety outcome

    In chronic hepatitis B, no significant side effects were observed with Talpha.

    In plain wordsIn people with chronic hepatitis B, no significant side effects were seen with thymosin alpha1.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeSide effects
    Study

    n = 98

    Comparator
    No treatment (control)
    Outcome group
    Adverse events · Whole body
    Studied dose
    1.6 mg twice weekly · subcutaneous · 26 or 52 weeksAs given in this study (human).

    Source sentences

    Summary
    No significant side effects were observed.
    1 context sentence
    Summary · context
    Ninety-eight patients with clinicopathologically proven chronic hepatitis B were randomly allocated to 3 groups
  6. 06HumanRandomized controlled trialEfficacy outcome

    In chronic hepatitis B, the complete virological response rate at 18 months was higher with a 26-week course of Talpha (40.6%) than with no treatment (9.4%).

    In plain wordsIn people with chronic hepatitis B, a 26-week course of thymosin alpha1 gave more complete virus clearance than no treatment (40.6% versus 9.4%).

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseComplete virological response at 18 months, 26-week course
    Study

    n: not reported in source

    Comparator
    No treatment (control)
    Outcome group
    Antiviral activity · Liver
    Studied dose
    1.6 mg twice weekly · subcutaneous · 26 weeksAs given in this study (human).

    Measurements

    Complete virological response rate
    40.6%
    group A
    Complete virological response rate
    9.4%
    group C

    Source sentences

    Summary
    The complete virological response rate (clearance of serum hepatitis B virus [HBV] DNA and hepatitis B e antigen [HBeAg]) was higher in group A (40.6%) and group B (26.5%) than in group C (9.4%) (group A vs. group C: P=.004
    1 context sentence
    Summary · context
    Ninety-eight patients with clinicopathologically proven chronic hepatitis B were randomly allocated to 3 groups
  7. 07HumanRandomized controlled trialEfficacy outcome

    In chronic hepatitis B, the complete virological response rate at 18 months with a 52-week course of Talpha (26.5%) was not significantly different from no treatment (9.4%).

    In plain wordsIn people with chronic hepatitis B, a 52-week course of thymosin alpha1 gave 26.5% complete virus clearance versus 9.4% with no treatment; not significant.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeComplete virological response at 18 months, 52-week course
    Study

    n: not reported in source

    Comparator
    No treatment (control)
    Outcome group
    Antiviral activity · Liver
    Studied dose
    1.6 mg twice weekly · subcutaneous · 52 weeksAs given in this study (human).

    Measurements

    Complete virological response rate
    26.5%
    group B
    Complete virological response rate
    9.4%
    group C

    Source sentences

    Summary
    The complete virological response rate (clearance of serum hepatitis B virus [HBV] DNA and hepatitis B e antigen [HBeAg]) was higher in group A (40.6%) and group B (26.5%) than in group C (9.4%) (group A vs. group C: P=.004; group B vs. group C: P=.068)
    1 context sentence
    Summary · context
    Ninety-eight patients with clinicopathologically proven chronic hepatitis B were randomly allocated to 3 groups
  8. 08HumanRandomized controlled trialEfficacy outcome

    In chronic hepatitis B, none of the responders lost hepatitis B surface antigen.

    In plain wordsIn people with chronic hepatitis B who responded to treatment, none lost the hepatitis B surface antigen.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeHBsAg loss in responders
    Study

    n: not reported in source

    Outcome group
    Antiviral activity · Liver
    Studied dose
    1.6 mg twice weekly · subcutaneous · 26 or 52 weeksAs given in this study (human).

    Source sentences

    Summary
    None of the responders lost hepatitis B surface antigen.
    1 context sentence
    Summary · context
    Ninety-eight patients with clinicopathologically proven chronic hepatitis B were randomly allocated to 3 groups

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.